Dose-response relationships

Concept

Dose-response relationships

T-121Home BU-404Threads regulation · structure

Statement

Potency, efficacy and the therapeutic window.

Why it matters

receptor-pharmacology establishes how a drug binds and activates a specific receptor; the dose-response relationship is what converts that single-molecule binding event into a quantitative, clinically usable description of how a whole organism responds as dose is varied. It supplies the vocabulary (potency, efficacy, therapeutic window) that pharmacokinetics' account of how drug concentration itself changes over time, and genomic-medicine's account of why different individuals may need different doses, both depend on to be clinically meaningful.

Hypotheses

Response is the result of drug binding to a specific, saturable population of receptors, following the law of mass action.Saturability is what gives the dose-response curve its characteristic sigmoid (S-shaped), rather than indefinitely rising, form: once essentially all available receptors are occupied, further dose increases can add little or no additional response, however much more drug is administered. A given drug concentration at the receptor produces a reproducible, defined level of response, independent of the history of prior doses (no significant tolerance or sensitisation over the timescale considered).Repeated dosing can shift a drug's effective dose-response relationship over time through tolerance (reduced response to the same dose after repeated exposure) or sensitisation (the reverse); the basic dose-response curve derived here describes a single-exposure relationship and needs this qualification for chronic dosing scenarios. Potency and efficacy are treated as conceptually independent properties of a drug.Potency (how much drug is needed to produce a given effect, indexed by $EC_{50}$) and efficacy (the maximum possible effect a drug can produce, $E_{\max}$) are governed by different underlying molecular properties (affinity and intrinsic activity respectively) and need not correlate with one another; a highly potent drug is not automatically highly efficacious, or vice versa.

Proof

[DR] \rightleftharpoons D + R, \qquad K_d = \frac{[D][R]}{[DR]}

Drug-receptor binding follows ordinary reversible mass-action equilibrium, exactly as any other saturable ligand-receptor interaction (receptor-pharmacology); $K_d$, the dissociation constant, quantifies how readily the drug and receptor dissociate once bound, and hence, inversely, the drug's binding affinity. A

\text{Fractional receptor occupancy rises with drug concentration but saturates as concentration exceeds } K_d, \text{ approaching but never exceeding full occupancy.}

At very low concentrations relative to $K_d$, occupancy rises roughly proportionally with concentration; at very high concentrations, essentially all receptors are already occupied, so further concentration increases add negligible additional occupancy, producing the characteristic plateau at the top of the curve. A

E = E_{\max}\cdot\frac{[D]^n}{EC_{50}^n + [D]^n}

Assuming response $E$ scales with receptor occupancy (Step 2), the same saturating mathematical form (the Hill equation) describes measured response as a function of dose, with $EC_{50}$ (the concentration producing half-maximal response) as the potency parameter and $E_{\max}$ as the efficacy parameter; $n$ (the Hill coefficient) captures the steepness of the transition, often reflecting cooperative binding. B

\text{Plotted against log(dose), Step 3's equation produces the characteristic sigmoid dose-response curve, with } EC_{50} \text{ at the curve's midpoint.}

Because pharmacological doses commonly span several orders of magnitude, dose-response data is conventionally plotted on a logarithmic dose axis, which converts the underlying saturation curve of Step 3 into a symmetric, S-shaped sigmoid whose inflection point falls exactly at $EC_{50}$ — a standard, directly readable graphical summary of both potency and efficacy simultaneously. A

Result

E = E_{\max}\cdot\dfrac{[D]^n}{EC_{50}^n+[D]^n}

Reading. A drug's dose-response behaviour is fully characterised by two largely independent parameters: $EC_{50}$ (potency, how much drug is needed) and $E_{\max}$ (efficacy, the ceiling on achievable effect), both readable directly from the sigmoid dose-response curve.

Scope. Applies to single-exposure, receptor-mediated pharmacological responses at or near equilibrium (Hypotheses); chronic dosing, where tolerance or sensitisation shift the effective relationship over time, requires the additional qualification noted in Hypotheses, t3.

Corollaries & converses

Comparing an $EC_{50}$ (desired therapeutic effect) against a separately measured $TD_{50}$ or $LD_{50}$ (toxic or lethal effect) yields the therapeutic index, the standard summary measure of a drug's safety margin, built directly on the potency/efficacy distinction established here.
Two drugs acting on the same receptor can be compared purely on potency (which has the lower $EC_{50}$) independently of comparing their efficacy (which has the higher $E_{\max}$); a full agonist and a partial agonist at the same receptor characteristically differ specifically in $E_{\max}$, not necessarily in $EC_{50}$, a distinction receptor-pharmacology develops further.
Converse: if two drugs' dose-response curves are found to be parallel (same shape and steepness, differing only in horizontal position along the log-dose axis), their mechanism of action at the receptor is typically inferred to be closely related, differing mainly in binding affinity rather than in fundamental mode of action.

Fails without

Drop saturable, mass-action binding (Hypotheses): without a finite, saturable receptor population, response would in principle continue rising indefinitely with dose rather than plateauing at $E_{\max}$; the characteristic sigmoid shape (Step 4), and the entire concept of a maximum achievable efficacy, depend specifically on this saturability.
Drop the assumption of independence between potency and efficacy (Hypotheses): without treating $EC_{50}$ and $E_{\max}$ as capturing genuinely different, separately variable molecular properties, a highly potent drug could mistakenly be assumed to also be highly efficacious (or vice versa); this conflation is exactly the source of the common clinical and conceptual error addressed below.

Common errors

Confusing potency ($EC_{50}$, the dose required for a given effect) with efficacy ($E_{\max}$, the maximum achievable effect); a drug can be highly potent (effective at a very low dose) yet have low efficacy (a low ceiling on achievable effect), or the reverse.
Assuming a drug with a lower $EC_{50}$ than another is automatically the "stronger" or clinically superior drug; if its $E_{\max}$ is also lower, the less potent drug may still produce a greater maximum therapeutic benefit at a sufficiently high, still-safe dose.
Reading the dose-response curve's midpoint on a linear, rather than logarithmic, dose axis, which distorts the curve's apparent shape and can lead to misreading $EC_{50}$ or the curve's steepness (Hill coefficient, Step 3).
Assuming the dose-response relationship for a chronically administered drug remains identical to its single-dose relationship; tolerance can shift the effective curve rightward (higher apparent $EC_{50}$) over repeated dosing (Hypotheses, t3).

Discussion

The sigmoid dose-response curve and its underlying occupancy theory trace back to Alfred Joseph Clark's work in the 1920s and 1930s, applying simple mass-action binding kinetics to pharmacological response for the first time, and the Hill equation's saturating mathematical form (Step 3) was originally developed by Archibald Hill in 1910 to describe cooperative oxygen binding by haemoglobin, later adapted directly to drug-receptor pharmacology because both phenomena share the same underlying saturable-binding mathematics.

The Hill coefficient $n$ in Step 3, beyond simply describing curve steepness, is often interpreted mechanistically: $n>1$ suggests positive cooperativity between multiple binding sites (successive binding events becoming progressively more favourable), $n<1$ suggests negative cooperativity, and $n=1$ is consistent with simple, non-cooperative single-site binding, though a measured Hill coefficient is a phenomenological curve-fitting parameter and does not, by itself, prove any specific number of binding sites is present.

Common misconception: that a drug's dose-response curve position tells you everything relevant about its clinical safety. $EC_{50}$ and $E_{\max}$ describe the desired therapeutic effect alone; a full assessment of clinical usability requires comparing this curve against a separate dose-response relationship for the drug's toxic or adverse effects, the basis of the therapeutic index (Corollaries).

Worked examples

\text{Drug A: } EC_{50}=2\ \text{nM},\ E_{\max}=100. \quad \text{Drug B: } EC_{50}=20\ \text{nM},\ E_{\max}=140.

Comparing the two drugs' curves directly: Drug A is more potent (lower $EC_{50}$, effective at a tenfold lower concentration), but Drug B has higher efficacy (higher $E_{\max}$, a greater maximum achievable effect), illustrating the independence of the two parameters established in the Hypotheses. A

\text{Drug A: more potent; Drug B: more efficacious — neither drug is simply "better" on both counts}

Reading. At very high, still-tolerable doses, Drug B may still outperform Drug A on the actual clinical outcome, despite Drug A working at far lower concentrations, since $E_{\max}$, not $EC_{50}$, sets the ceiling on total achievable effect.

Scope. Comparisons of this kind are standard in drug selection, but require additionally weighing each drug's dose-response curve for toxicity (therapeutic index, Corollaries) before any overall clinical judgement of superiority.

Problems

Drug X has $EC_{50}=5\ \mu\text{M}$ for its desired effect and $TD_{50}=50\ \mu\text{M}$ for a defined toxic effect. Calculate the therapeutic index and comment briefly on what a larger value would indicate.
Solution
Therapeutic index $=TD_{50}/EC_{50}=50/5=10$. A larger therapeutic index indicates a wider safety margin between the dose producing the desired effect and the dose producing toxicity, meaning there is more room for dosing error or individual variation in drug sensitivity before toxicity becomes likely.
Two partial agonists at the same receptor are compared: both have identical $EC_{50}$ values, but Drug C has $E_{\max}=40$ and Drug D has $E_{\max}=70$ (relative to a full agonist's $E_{\max}=100$). Explain what this indicates about their mechanism at the receptor, using Step 3.
Solution
Because $EC_{50}$ (potency, related to receptor binding affinity) is identical for both drugs, but $E_{\max}$ (efficacy, related to the drug's ability to activate the receptor once bound, its intrinsic activity) differs, the two drugs bind the receptor with similar affinity but differ in how effectively that binding is translated into receptor activation; Drug D is the more efficacious partial agonist of the two, despite neither drug producing the full agonist's maximum response.
A researcher plots a drug's response against dose on a linear (not logarithmic) concentration axis and observes what looks like a steep, almost step-like rise rather than a smooth sigmoid. Explain why switching to a logarithmic dose axis is standard practice, referencing Step 4.
Solution
Pharmacological doses commonly need to span several orders of magnitude to capture the full range from negligible to maximal effect; on a linear axis, this wide range compresses the meaningful transition region into a visually narrow, steep-looking segment near the low end of the axis. Plotting against log(dose) instead (Step 4) spreads this transition out evenly, producing the characteristic, symmetric sigmoid shape whose midpoint directly and legibly identifies $EC_{50}$, which is why log-dose plotting is the field's standard convention.